Nolato ABFRA:NBF -3.68%80 Return-on-Tangible-Equity is 20.82% as of Mar. 2026, which is 37% below its 10-year median of 33.06. GuruFocus rates FRA:NBF with a GF Score™ of 80/100 and a GF Value™ of €4.76 (Fairly Valued). The stock has 2 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Nolato AB ranks better than 85.13% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Nolato AB's annualized net income for the quarter that ended in Mar. 2026 was €67.2 Mil. Nolato AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €322.8 Mil. Therefore, Nolato AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 20.82%.
The historical rank and industry rank for Nolato AB's Return-on-Tangible-Equity or its related term are showing as below:
FRA:NBF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 15.29 Med: 33.06 Max: 56.04
Current: 23
During the past 13 years, Nolato AB's highest Return-on-Tangible-Equity was 56.04%. The lowest was 15.29%. And the median was 33.06%.
FRA:NBF's Return-on-Tangible-Equity is ranked better than 85.13% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs FRA:NBF: 23.00
Nolato AB (FRA:NBF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Nolato AB Return-on-Tangible-Equity Related Terms
Nolato AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Nolato AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NBF vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Nolato AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nolato AB Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nolato AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Nolato AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.82% mean?
Nolato AB (FRA:NBF) has a Return-on-Tangible-Equity of 20.82% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Nolato AB and its competitors. This is 37% below median its historical median of 33.06. Over the past decade, Nolato AB's Return-on-Tangible-Equity has ranged from 15.29 to 56.04. According to the industry distribution chart, Nolato AB ranks #113 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 14.9%.
Is Nolato AB's Return-on-Tangible-Equity too high?
Nolato AB's current Return-on-Tangible-Equity of 20.82% is 37% below median its 10-year median of 33.06. Over the past 10 years, this metric has ranged from a low of 15.29 to a high of 56.04. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. Nolato AB's value of 20.82% is 416.6% above this industry median. Based on the distribution chart, Nolato AB ranks #113 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nolato AB has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nolato AB's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nolato AB ranks #113 out of 760 companies for Return-on-Tangible-Equity. This places Nolato AB in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.03. Nolato AB's value of 20.82% is 416.6% above this benchmark. Historically, Nolato AB's own Return-on-Tangible-Equity has ranged from 15.29 to 56.04 over the past decade. While the company's 10-year median is 33.06 vs. the industry median of 4.03, Nolato AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nolato AB's current Return-on-Tangible-Equity of 20.82% is 416.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Nolato AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nolato AB's current Return-on-Tangible-Equity is 20.82%, which is 37% below median its own 10-year median of 33.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nolato AB stock overvalued right now?
Based on GuruFocus' analysis, Nolato AB (FRA:NBF) is currently considered Fairly Valued. The stock's GF Value™ is €4.76, compared to a current price of €4.32 — trading 9.3% below its estimated fair value. The current Return-on-Tangible-Equity is 20.82%, which is 37% below median its 10-year median of 33.06 and 416.6% above the Medical Devices & Instruments industry median of 4.03. Nolato AB's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Nolato AB (FRA:NBF), the current Return-on-Tangible-Equity is 20.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nolato AB (FRA:NBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nolato AB stock appears to be undervalued.
The current stock price of €4.32 is trading 9.3% below its estimated GF Value™ of €4.76.
GuruFocus considers Nolato AB to be Fairly Valued.
Key valuation signals for FRA:NBF:
Return-on-Tangible-Equity: 20.82% (37% below median its 10-year median of 33.06)
GF Value™: €4.76 vs. price of €4.32 (9.3% below fair value)
Industry Position: 416.6% above the Medical Devices & Instruments median (#113 of 760)
No single metric tells the full story. See the FRA:NBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nolato AB is a Swedish company that develops and manufactures plastic, silicone, and thermoplastic elastomer products. The firm's operations are organized into two segments: Medical Solutions and Engineered Solutions. The company generates the majority of its revenue from the Medical Solutions segment, which is engaged in the development and manufacture of complex product systems and components for medical devices, the pharmaceutical industry, and diagnostics. The Engineered Solutions design, development, industrialization, and manufacture of subsystems and ready-packaged products for a range of industries, including offerings within EMC and thermal solutions. Geographically, the firm generates key revenue from the Rest of Europe and the United States.
80GF Score
Get the complete analysis for FRA:NBF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NBF has been successfully added to your 
